Baseline CRP Levels and Thromboembolic Events: A Retrospective Case-Control Study CRP Levels and Thromboembolic Events
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 15 No. 4 (2025),
30 October 2025
,
Page 1-6
https://doi.org/10.22037/ijmtfm.v15i4.50108
Abstract
Background: Several studies have proposed that C-reactive protein (CRP) levels could serve as a potential indicator for predicting coronavirus disease 2019 (COVID-19); however, the findings have been inconsistent. This study aims to evaluate the relationship between baseline CRP and thromboembolic complications in patients with COVID-19.
Methods: This case-control study involved two groups of COVID-19 patients admitted to Shahid Beheshti Hospital in Kashan: those with thromboembolic events (TEEs) and those without. Eligible patients were enrolled through simple random sampling based on predefined inclusion criteria. Data on patient demographics, clinical findings, and vital signs were collected using a standardized checklist.
Results: We examined 70 patients with COVID-19 who experienced TEEs and 70 patients who did not. The most common underlying conditions in both groups were high blood pressure, affecting 21 individuals (30%), and diabetes, affecting 25 individuals (35.7%) (P > 0.05). In the control group, the most prevalent clinical symptoms associated with TEEs were shortness of breath, reported by 60 individuals (85.7%), and cough, reported by 46 individuals (65.7%). The incidence of shortness of breath in the case group was significantly higher than in the control group (P < 0.001). Additionally, the two groups showed significant differences in breathing rate (P = 0.002) and heart rate (P = 0.016). There was also a significant difference in CRP levels between the two groups (P = 0.038), with patients in the case group exhibiting higher CRP levels.
Conclusion: This finding indicated that the level of CRP in patients with TEEs was significantly higher than in the control group. These results suggest that CRP may serve as an effective marker for identifying patients at risk of TEEs.
- Thromboembolic events, COVID-19, C-reactive protein
How to Cite
References
[1] Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S. COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. Int Immunopharmacol. 2021;90:107247. [DOI: 10.1016/j.intimp.2020.107247]
[2] Parsa AFZ, Pouraliakbar H, Raisi-Estabragh Z, Houshmand G. Myocardial infarction with non-obstructive coronary artery in a middle-aged woman with COVID-19. Oxf Med Case Rep. 2022;2022(2):omac001. [DOI: 10.1093/omcr/omac001]
[3] Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17-41. [DOI: 10.1002/JLB.3COVR0520-272R]
[4] Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-60. [DOI: 10.1038/s41569-020-0360-5].
[5] He J, Wu B, Chen Y, Tang J, Liu Q, Zhou S, et al. Characteristic electrocardiographic manifestations in patients with COVID-19. Can J Cardiol. 2020;36(6):966.e1-966.e4. [DOI: 10.1016/j.cjca.2020.03.028].
[6] Singh B, Goyal A, Patel BC. C-Reactive Protein: Clinical Relevance and Interpretation. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. [Link]
[7] Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: A systematic review. Expert Rev Hematol. 2020;13(11):1265-75. [DOI: 10.1080/17474086.2020.1831383]
[8] Zlatković-Švenda M, Ilić A, Soldatović I, Živković A, Šuvakov S, Živković M, et al. The new occurrence of antiphospholipid syndrome in severe COVID-19 cases with pneumonia and vascular thrombosis could explain the post-COVID syndrome. Biomedicines. 2025;13(2). [DOI: 10.3390/biomedicines13020438]
[9] Tajbakhsh A, Gheibi Hayat SM, Sahebkar A, Tavakol S, Rezaei N. COVID-19 and cardiac injury: Clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther. 2021;19(3):345-57. [DOI: 10.1080/14787210.2021.1843053]
[10] Malekpour M-R, Ghamari S-H, Shahyad S, Shakiba Y, Ghasemi E, Naderi N, et al. The burden of metabolic risk factors in North Africa and the Middle East, 1990–2019: findings from the Global Burden of Disease Study. EClinicalMedicine. 2023;60:102022. [DOI: 10.1016/j.eclinm.2023.102022]
[11] Soleimani A, Hashemy SI, Yari A, Asghari S, Mashhadizadeh S, et al. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma. Biochimie. 2020;176:21-30. [DOI: 10.1016/j.biochi.2020.05.006]
[12] Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-7. [DOI: 10.1016/j.thromres.2020.04.013]
[13] Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500. [DOI: 10.1182/blood.2020006520]
[14] Allan M, Grimsrud A, Oyunge OA, Cambiano V, del Amo J, Johnson S, et al. The World Health Organization COVID-19 surveillance database. Int J Equity Health. 2022;21(Suppl 3):167. [DOI: 10.1186/s12939-022-01798-8]. PubMed
[15] Mitiku HZ, Damot TE, Mengistu SA, Tsegaye YT. Risk stratification and contributing factors of deep vein thrombosis among patients admitted at Debre Markos comprehensive specialized hospital, Ethiopia in 2024. Front Med (Lausanne). 2024;11:1470212. [DOI: 10.3389/fmed.2024.1470212]
[16] da Silveira WC, Pisani AC, de Almeida FA, Azevedo LCP, Carvalho CRR, de Souza HP, et al. Predictors of venous thromboembolism in COVID-19 patients: results of the COVID-19 Brazilian Registry. Intern Emerg Med. 2022;17(7):1863-78. [DOI: 10.1007/s11739-021-02871-1]
[17] García-Ortega A, Oscullo G, Albacar N, Calvillo P, Sarriá C, Castillo C, et al. Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection. J Infect. 2021;82(2):261-9. [DOI: 10.1016/j.jinf.2020.09.033]
[18] Yadollahi M, Rafiemanesh H, Motamedfar A, Mirjalili M, Rasekhi A, Jamalnia S. Investigating the prevalence of and predictive and risk factors for pulmonary embolism in patients with COVID-19 in Nemazee Teaching Hospital. Blood Res. 2023;58(3):127-32. [DOI: 10.5045/br.2023.2022124]
[19] Quist-Paulsen P, Næss IA, Cannegieter SC, Romundstad PR, Christiansen SC, Rosendaal FR, et al. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica. 2010;95(1):119-125. [DOI: 10.3324/haematol.2009.011866]
[20] Hald EM, Brækkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Brox J, et al. High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromsø study. Haematologica. 2011;96(8):1189-94. [DOI: 10.3324/haematol.2010.034991]
[21] Shaw RJ, Anderson LA, Kenyon JC, Devisetty R, Benjamin L, Dweck MR, et al. COVID-19 and immunothrombosis: emerging understanding and clinical management. Br J Haematol. 2021;194(3):518-29. [DOI: 10.1111/bjh.17634]
[22] ATTACC, ACTIV-4a, REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med. 2021;385(9):790-802. [DOI: 10.1056/NEJMoa2105911]
[23] Zhu J, Fuda F, Ravioli S, Peng C, Stanga Z, Frey BM, et al. Combined coagulation and inflammation markers as predictors of venous thrombo-embolism and death in COVID-19. Front Med (Lausanne). 2024;11:1399335. [DOI: 10.3389/fmed.2024.1399335]
[24] Simani M, Simani M, Zohreh M, et al. Evaluation of 10 Years Atherosclerotic Cardiovascular Risk, Vitamin D and Metabolic Profiles in Smokers: Atherosclerotic cardiovascular disease and smokers. Int J Med Toxicol Forensic Med. 2025;15(2). [DOI: 10.32598/ijmtfm.15.02.76]
- Abstract Viewed: 73 times
- PDF Downloaded: 94 times